GSK
GSK
895 hedge funds and large institutions have $11.1B invested in GSK in 2023 Q4 according to their latest regulatory filings, with 127 funds opening new positions, 270 increasing their positions, 345 reducing their positions, and 63 closing their positions.
118% more call options, than puts
Call options by funds: $227M | Put options by funds: $104M
102% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 63
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
7% more capital invested
Capital invested by funds: $10.4B → $11.1B (+$753M)
6% more funds holding
Funds holding: 846 → 895 (+49)
0.3% more ownership
Funds ownership: 6.98% → 7.28% (+0.3%)
22% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 345
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$343M |
| 2 |
Holocene Advisors
New York
|
+$115M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$89.6M |
| 4 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$77.3M |
| 5 |
AC
Armistice Capital
New York
|
+$68.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$159M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$107M |
| 3 |
Goldman Sachs
New York
|
-$43.6M |
| 4 |
Millennium Management
New York
|
-$42.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$38.3M |
GSK Hedge Fund Activity: Q4 2023 in Review
895 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2023, worth a combined $11.1B — up 7.3% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 127 funds opened new GSK positions and 63 closed out — a net gain of 64 holders — while 270 added to existing stakes and 345 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $343M. The largest seller was Deutsche Bank, cutting an estimated $159M.
- 895 institutional investors held GSK (GSK) as of Q4 2023, up from 846 in Q3 2023.
- Funds reported $11.1B of GSK stock for Q4 2023, up 7.3% quarter-over-quarter.
- 127 funds opened new GSK positions in Q4 2023 and 63 closed out, a net change of +64 holders.
- The largest GSK buyer in Q4 2023 was Morgan Stanley, an estimated $343M added.
- The largest GSK seller in Q4 2023 was Deutsche Bank, an estimated $159M sold.
Based on aggregated 13F filings for Q4 2023.